Apogee Therapeutics chairman Mark McKenna (L), and CEO Michael Henderson
August 21, 2023 07:30 AM EDT
People

Af­ter Prometheus sale, Mark McKen­na heads to an­oth­er au­toim­mune biotech as chair of Apogee

Kyle LaHucik

Senior Reporter

Af­ter Mark McKen­na sold a biotech for $10.8 bil­lion, the ex­ec­u­tive re­cruiters like­ly came knock­ing, try­ing to poach the CEO who took an im­munol­o­gy and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times